Post on 13-Mar-2018
Notes:
800-624-9600 rmsmedicalproducts.com
RMS Medical Products24 Carpenter RoadChester, NY 10918 USA
RHI_BR_ABXSolutionsGuide_03-10004vD
The FREEDOM60® and FreedomEdge™ Syringe Infusion Systems and RMS Precision Flow Rate Tubing™ are registered trademarks of RMS Medical Productsand are compliant with Medical Device Directive 93/42/EEC. RMS Medical Products is ISO 13485 certi�ed. © 2016 RMS Medical Products; All Rights Reserved.
Antibiotic HomeInfusion Solutionswith RMS Medical Products
FREEDOM60® Syringe Infusion Pumpwith Travel Pouch
Additional Travel Pouch - blackOptional Zebra Travel Pouch - pattern
F10050
F10090
F10080
Low Flow Rate Kit*Item # L20KTContains: (2) F30 (5) F45 (5) F60 (4) F120 (4) F180
Item #
FreedomEdge™ Syringe Infusion Pumpwith Travel Pouch
Additional FreedomEdge™ Travel Pouch
F10020
347400
Item #
F120F180
F30F45F60
Item #
For assistance indetermining theright tubing foryour needs,please call us at800-624-9600.
Available uponrequest. Call us
at 800-624-9600
(individual tubes)*These are just a sample of the wide range of tubing sets we o�er.
For 60ml syringes
For 20ml and 30ml syringes
Product Listing
FREEDOM60® �at training pumps
page 3
Low Flow Sets*
RMS Freedom syringe infusion systems (Freedom DynEQ™ systems) allowantibiotic infusion anywhere, by anyone. These revolutionary systems makeIV antibiotic infusion easier than ever before for patients and providers.
RMS makes your home infusion experience simpler. We o�er world classsupport and training materials for the simplest reusable pumps on themarket. The Freedom DynEQ™ systems are the only ones designed toemploy dynamic equilibrium – automatically delivering accurate �owrates, with patient-responsive safety built-in.
Antibiotic Home Infusion Solutionsfrom RMS Medical Products
• Proven patient- and budget-friendly infusion systems The FREEDOM60® and the FreedomEdge™ are the only infusion pumps designed to employ Dynamic Equilibrium. This means the Freedom DynEQ™ systems operate at a safe, low pressure and naturally adjust the �ow rate in direct proportion to any pressures developed inside the patient. Freedom pumps self-adjust to �ll volume and use trusted materials made of DEHP-free PVC.
• Increased pro�tability/reduced expenses with portable, low maintenance pumps These pumps are engineered and tested to meet provider needs and budgets. Using a reimbursable and reusable pump lowers costs, creating better bottom line pro�tability. Our pumps are low maintenance with no power or batteries needed.
• Eliminates hidden complexity and variables of elastomeric devices With Freedom DynEQ™ systems, there is less variability in �ow rate compared to elastomerics. There are no complicated elastomeric timing and freezing requirements and accurate infusions are ensured with RMS Precision Flow Rate Tubing™. There are a variety of �ow rates available to select infusion times of minutes to days.
• Fit almost any dose into 60ml, 30ml, and 20ml syringes The FREEDOM60® accommodates 60ml syringes and the FreedomEdge™ accommodates both 20ml and 30ml syringes. Take advantage of the bene�ts of higher concentrations in plastic syringes. Standardizing your infusions in plastic syringes creates better pharmacy e�ciency work�ow and reduces waste, bene�tting both pharmacy and patient alike.
• Go green – environmentally friendly with less medical waste The Freedom DynEQ™ systems are environmentally friendly, dramatically reduce the use of materials and disposable plastic while generating less hazardous and medical waste.
• Antibiotic home infusions are better with the RMS FREEDOM60® and FreedomEdge™ These Freedom DynEQ™ systems are preferred by home healthcare professionals because they are simple mechanical devices with no programming involved. Patients can be trained in as little as 15 minutes. They’re easy to use because they never stall and require no thawing, no cassettes, and no batteries.
page 2
page 5
Patient Pro�le:Ages 18-56 yearsThere were 144 patients
over a period of 3 monthswho met inclusion criteria.
S7
142128
T3
10172431
W4
111825
T5
121926
F6
132027
M29
162330
S18
152229
Therapy lasted from2 to 6 weeks per patient.
S29
162330
T295
121926
W306
132027
T317
142128
F18
152229
M284
111825
S273
101724
S5
1219262
T18
152229
W29
162330
T3
10172431
F4
1118251
M
7142128
S
6132027
Disclosure: Authors of this presentation have the following to disclose concerning possible �nancial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this pre-sentation: William E. Miller, Jr., RPh: CarePoint Partners, a BioScrip company; Mala Crossley, BS, PharmD: Crossley LLC This poster was funded by RMS Medical Products, a dba of Repro-Med Systems, Inc.
The Use of a Portable Syringe Infusion System for Antibiotic InfusionsContributing Authors:
William E. Miller, Jr., RPh1 and Mala Crossley, BS, PharmD2 1CarePoint Partners, a BioScrip company, 2Crossley LLC
Background:The need for an inexpensive reusable infusion pump for the delivery of antibiotics toLouisiana Medicaid patients was identi�ed. Louisiana Medicaid does not reimburse forelastomeric pumps. Intravenous push administration, rate controlled gravity infusion,stationary pumps, and ambulatory pumps are not always feasible based on drug or patientcharacteristics. Syringe pumps were identi�ed as a potential option, with an evaluation conducted to compare available types, modes of operation (electronic vs. mechanical), syringe size, ease of operation, satisfaction, associated disposables and operating costs.A portable syringe infusion system was identi�ed as the most cost e�ective, reusable,easy to operate infusion pump alternative for this evaluation.
Purpose:Evaluate a portable syringe infusion system as a viable option for antibiotic infusionsbased on economics, convenience, training, satisfaction, and patient safety.
Methods:Patient selection criteria included adult prescribed intravenous cephalosporins (suchas ceftriaxone and cefazolin), every eight hours or less, for a duration of 2-6 weeks, and reimbursed by Louisiana Medicaid. After training of select sta� by the FREEDOM60®pump manufacturer, additional sta� were trained as the control group. Standardizeddata collection tools were used for patient interviews. Data collected in the pumpevaluation included cost of use and reimbursement, ease of use, training time, portability,accuracy, general satisfaction, and overall pump safety. The rating scale used by patientswas Very Poor, Poor, Fair, Good, and Very Good.
Results:There were 144 patients over a period of 3 months who met inclusion criteria. Costsavings achieved were approximately $6/day for every eight hour dosing, compared to anelastomeric pump. Louisiana Medicaid reimburses for the portable syringe infusion systemand supplies at approximately $171/month, but will not cover elastomeric pumps. Timerequired to train home health agency (HHA) nurses was approximately 30 minutes. Trainingtime for patients to achieve successful return demonstration was approximately 15-30minutes. Initially, priming of the tubing was performed by the pharmacy, however thiswas changed to patient instruction after several reports of pump sets breaking o� whenrefrigerated. No other safety issues were reported. Overall satisfaction rating fromclinicians and patients for the portable syringe infusion system was Very Good.
Discussion:Patients and clinicians observed a number of advantages to the portable syringe infusionsystem, including convenience, portability, lightweight and easy to operate. Training timewas considered reasonable by HHA and infusion pharmacy sta�, although no directcomparison was performed with regards to other administration methods. The one issuethat occurred at the start, broken pump sets that was associated with refrigeration, wasrecti�ed immediately and tubing manufacturer noti�ed. This tubing issue did not causeany signi�cant costs/unscheduled deliveries, or patient/clinician dissatisfaction.
Conclusion:The portable syringe infusion system is a cost e�ective, reimbursable alternative foranti-infective drug administration for Louisiana Medicaid patients.
The Use of a Portable Syringe Infusion System for Antibiotic InfusionsCase Study:
page 4
page 6
Cost Savings withSyringe Infusion Pump
Cost savings achievedwere approximately
$6/day for every eighthour dosing, comparedto an elastomeric pump.
$200
$175
$150
$125
$100
$75
$50
$25
$0
$171
$0Syringe
Infusion PumpElastomeric
Pump
Monthly Medicaid Reimbursement
economics
$275
$250
$225
$200
$175
$150
$125
$100
$75
$50
$25
$0
$252
2 WKS
3 WKS
6 WKS
5 WKS
4 WKS
$84
Increasing Expense of Elastomerics– Per Patient –
$6 More at 3x Dose/Day:$6/day = $84 (over 2 weeks) to $253 (over 6 weeks)
SyringeInfusion Pump
≤ 0.4 ml*
ElastomericPump
≤ 3 ml*
Residual VolumeThe elastomeric retains
7.5X more volumethan the
syringe system.*
4 ml
3 ml
2 ml
1 ml
0
*Based on manufacturer information
Total cost of goods savings using the syringe infusion pump for 144 patients was between $12,000 and $36,000 for the duration of the study.
The Use of a Portable Syringe Infusion System for Antibiotic Infusions
page 7
SyringeInfusion
Pump30 min
Agency TrainingTime required to train home health agency
(HHA) nurses was approximately 30 minutes.
Patient TrainingTraining time for patients
to achieve successful return demonstration
was approximately 15-30 minutes.
15 minto
30 min
Step 5
Step 4
Step 3
Step 2
Step 1
Step 10
Step 9
Step 8
Step 7
Step 6
Syringe infusion systemhas only two controls
for patients to operate.
Patients and clinicians observed a number of
advantages to the portable syringe infusion system,
including convenience, portability, ease of operation and the
pump’s light weight.
training
The Use of a Portable Syringe Infusion System for Antibiotic Infusions (continued)
convenience
satisfaction
patient safety
The syringe infusion pump o�ers patientsa safe and convenient option to be
ambulatory while doing their therapy.
portability
page 9
Con�dently deliver the most common antibiotics, with excellent stabilityin 20ml, 30ml and 60ml polymer syringes.
Higher concentrations can mean greater stability, and less volume for�uid-restricted patients.
Use RMS Precision Flow Rate Tubing Sets™ under the same institutionalprotocols as gravity sets – less waste than single-�ll elastomeric devices.
RMS works with the pharmacy’s clinical team for a seamless transitionfrom other delivery devices. We o�er in-service training, WebEx™pharmacy and nurse training, as well as a suite of patient trainingmaterials to minimize and enhance teaching and troubleshooting time.This all adds up to greater patient satisfaction.
The Pharmacist's Guide to SyringeStability for Freedom DynEQ™Infusion Systems
page 8
The Clinical Bene�ts are Clear-Cut.Freedom DynEQ™Infusion Systems Leading Elastomeric
Maintains full pressure at end ofinfusion – no back-�ow
Excellent stability in polymer syringes,tested by leading institutions
+/- 7% accuracy, �ll to any volume,not position sensitive
Accuracy not a�ected by time
No need to thaw
DEHP-free
Delivery times from minutes to days,small volumes are no problem
Works great with viscous medications
Pressure may drop dramatically at endof infusion – risk of blood re�ux
Acceptable stability, based oncon�dential company testing
+/- 15% at speci�c �ll volumes, must bepositioned near level of catheter site
Must be �lled 4 hours before infusion
Table to calculate time to room temp-erature, volume restrictions forevery size
Contains DEHP plasticizer – bannedin Europe
Delivery times from 30 minutes to5 hours
Only to be used with water-likeviscosities
Freedom DynEQ™ infusion systems are designed with home infusionpatients and professionals in mind. The Freedom systems deliver a safe,cost-e�ective infusion and ease of use comparable to an elastomeric.
Pharmacist's guideto Syringe Stability
for FREEDOM60®
5 mg/mL PI: Merck; Whitehouse Station NJ, 2014.Imipenim/cilastin (Primaxin®) NS, D5W: 24h
50,000 U/mL PI: P�zer; New York NY, 2005.Penicillin G (P�zerpen®) W, NS, D5W: 7d
0.1125 g/mL PI: P�zer, Wyeth; Philadelphia PA, 2012.Piperacillin/tazobactam (Zosyn®) W, NS, D5W: 7d
12.5 mg/mL Dienstag & Neu. Clin Med 1975; 82:13-9.Tobramycin (Nebcin®) W, NS, D5W: 30d
≤25 mg/mL ASHP's Handbook on Injectable Drugs, 18th Edition, 2015.Vancomycind W, NS, D5W: ≥14d
50 mg/mLFugit KD, Anderson BD. Antibiotic Stability in Freedom60Syringe Report By HealthTek™ and the University ofKentucky, Lexington. Chester, NY: RMS; 2015.
Meropenem (Merrem®)W: 44hNS: 40h
D5W: 25h
200 mg/mL (W, D5W)100 mg/mL (NS)
Fugit KD, Anderson BD. Antibiotic Stability in Freedom60Syringe Report By HealthTek™ and the University ofKentucky, Lexington. Chester, NY: RMS; 2015.
Oxacillin (Oxacillin®)cW: Not recommended at 4°C; 84h at RT
NS: ≥2wkD5W: Not recommended at 4°C; 42h at RT
40 mg/mL100 to 200 mg/mL
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: GlaxoSmithKline; Research Triangle Park NC, 2004.3. Bornstein et al. Am J Hosp Pharm. 1974;31:296-98.
CI: Cefazolin (Ancef®)NS: 56d; D5W: 91d1
W, NS, D5W: 102-14d3RT high conc− W: 4d3; NS, D5W: 24h2
60 mg/mL100 mg/mL
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: GlaxoSmithKline; Research Triangle Park NC, 2004.3. PI: Hospira Worldwide; Lake Forest IL, 2014.
CI: Ceftazidime(Fortaz®, Tazicef®)
NS: 10d; 1.5d at RTW, NS, D5W: 7d at 4°C; 24h1 at RT2,3
50 mg/mLFugit KD, Anderson BD. Antibiotic Stability in Freedom60Syringe Report By HealthTek™ and the University ofKentucky, Lexington. Chester, NY: RMS; 2015.
CI: Meropenem (Merrem®)
W: 44hNS: 40h
D5W: 25hW, NS: 8h at RTD5W: 5h at RT
20 mg/mL100 mg/mL
1. Fugit KD, Anderson BD. Antibiotic Stability in Freedom60Syringe Report By HealthTek™ and the University ofKentucky, Lexington. Chester, NY: RMS;2015.2. Walker SE et al. Can J Hosp Pharm. 2015;68:121-6.
Ertapenem (Invanz®)b W, NS: 4.5d; D5W: 28h1NS: 48h2
PI: Sano�-Aventis; Bridgewater NJ, 2007.CI: Cefotaxime (Claforan®) W, NS, D5W: 5dW, NS, D5W: 24h at RT100 mg/mL
1. PI: P�zer; New York NY, 2005.2. ASHP's Handbook on Injectable Drugs, 18th Edition, 2015.CI: Penicillin G (P�zerpen®) W, NS, D5W: 7d1
NS, D5W: 24h at RT250,000 U/mL
PI: P�zer, Wyeth; Philadelphia PA, 2012.CI: Piperacillin/tazobactam(Zosyn®)
W, NS, D5W: 7dW, NS, D5W: 24h at RT0.1125 g/mL
30/15 mg/mL20/10 mg/mL PI: P�zer; New York NY, 2014.
Antibiotic (brand name) ReferenceConcentration Stability at 4˚C
Ampicillin 30 mg/mL≤20 mg/mL
Ampicillin/sulbactam(Unasyn®)
W: 48h; NS: 24hW: 72h; NS: 48h; D5W: 1h PI: P�zer; New York NY, 2010.
W, NS: 48hW, NS: 72h; D5W: 4h
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: Genentech USA; South San Francisco CA, 2015.Ceftriaxone (Rocephin®) NS: 23d; D5W: 26d1
W, NS D5W: 10d2
100 mg/mL PI: Bristol-Myers Squibb; Princeton NJ, 2013Aztreonam (Azactam®) W, NS: 7d
18 mg/mL ASHP's Handbook on Injectable Drugs, 18th Edition, 2015.Clindamycin (Cleocin®)a W, NS, D5W: 30d
100 mg/mL PI: Sano�-Aventis; Bridgewater NJ, 2007.Cefotaxime (Claforan®) W, NS, D5W: 5d
40 mg/mL100 to 200 mg/mL
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: GlaxoSmithKline; Research Triangle Park NC, 2004.3. Bornstein et al. Am J Hosp Pharm. 1974; 31:296-98.
Cefazolin (Ancef®) NS: 56d; D5W: 91d1W, NS, D5W: 102-14d3
60 mg/mL100 mg/mL
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: GlaxoSmithKline; Research Triangle Park NC, 2004.3. PI: Hospira Worldwide; Lake Forest IL, 2014.
Ceftazidime (Fortaz®, Tazicef®) NS: 10d1W, NS, D5W: 7d2,3
20 mg/mLBing CM, Nowobilski-Vasilios A, American Society of Health-System P. Extended stability for parenteral drugs. Bethesda, Md.:American Society of Health-System Pharmacists; 2013.
Daptomycin (Cubicin®) NS: 10d
40 mg/mL100 mg/mL
This document is intended forconvenience only. Final dose
and delivery decisions are thehealthcare provider's responsibility.
CID5W
NSRTW
= continuous infusion= 5% dextrose in water= normal saline (0.9%)= room temperature= sterile water for injection.
page 10
Refrigerated or frozen, clindamycin formscrystals which must be resolubilizedbefore administration. Clindamycin isincompatible with natural rubberclosures because it may extract toform crystal particulates, so RT storagein disposable syringes should be limitedto a few days.
Ertapenem should not be reconstitutedor mixed with solutions containingdextrose.
Oxacillin sodium can be extremelyirritating to veins at higher concentrations.
Administer higher concentrations via acentral line to avoid irritation; durations>90 min may be required if Redmansyndrome develops.
ASHP's Handbook on Injectable Drugs,18th Edition, 2015.
a
Special Notes:
b
c
d
5 mg/mL PI: Merck; Whitehouse Station NJ, 2014.Imipenim/cilastin (Primaxin®) NS, D5W: 24h
50,000 U/mL PI: P�zer; New York NY, 2005.Penicillin G (P�zerpen®) W, NS, D5W: 7d
0.1125 g/mL PI: P�zer, Wyeth; Philadelphia PA, 2012.Piperacillin/tazobactam (Zosyn®) W, NS, D5W: 7d
12.5 mg/mL Dienstag & Neu. Clin Med 1975; 82:13-9.Tobramycin (Nebcin®) W, NS, D5W: 30d
≤25 mg/mL ASHP's Handbook on Injectable Drugs, 18th Edition, 2015.Vancomycind W, NS, D5W: ≥14d
50 mg/mLFugit KD, Anderson BD. Antibiotic Stability in Freedom60Syringe Report By HealthTek™ and the University ofKentucky, Lexington. Chester, NY: RMS; 2015.
Meropenem (Merrem®)W: 44hNS: 40h
D5W: 25h
200 mg/mL (W, D5W)100 mg/mL (NS)
Fugit KD, Anderson BD. Antibiotic Stability in Freedom60Syringe Report By HealthTek™ and the University ofKentucky, Lexington. Chester, NY: RMS; 2015.
Oxacillin (Oxacillin®)cW: Not recommended at 4°C; 84h at RT
NS: ≥2wkD5W: Not recommended at 4°C; 42h at RT
40 mg/mL100 to 200 mg/mL
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: GlaxoSmithKline; Research Triangle Park NC, 2004.3. Bornstein et al. Am J Hosp Pharm. 1974;31:296-98.
CI: Cefazolin (Ancef®)NS: 56d; D5W: 91d1
W, NS, D5W: 102-14d3
RT high conc− W: 4d3; NS, D5W: 24h2
60 mg/mL100 mg/mL
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: GlaxoSmithKline; Research Triangle Park NC, 2004.3. PI: Hospira Worldwide; Lake Forest IL, 2014.
CI: Ceftazidime(Fortaz®, Tazicef®)
NS: 10d; 1.5d at RTW, NS, D5W: 7d at 4°C; 24h1 at RT2,3
50 mg/mLFugit KD, Anderson BD. Antibiotic Stability in Freedom60Syringe Report By HealthTek™ and the University ofKentucky, Lexington. Chester, NY: RMS; 2015.
CI: Meropenem (Merrem®)
W: 44hNS: 40h
D5W: 25hW, NS: 8h at RTD5W: 5h at RT
20 mg/mL100 mg/mL
1. Fugit KD, Anderson BD. Antibiotic Stability in Freedom60Syringe Report By HealthTek™ and the University ofKentucky, Lexington. Chester, NY: RMS;2015.2. Walker SE et al. Can J Hosp Pharm. 2015;68:121-6.
Ertapenem (Invanz®)b W, NS: 4.5d; D5W: 28h1
NS: 48h2
PI: Sano�-Aventis; Bridgewater NJ, 2007.CI: Cefotaxime (Claforan®) W, NS, D5W: 5dW, NS, D5W: 24h at RT100 mg/mL
1. PI: P�zer; New York NY, 2005.2. ASHP's Handbook on Injectable Drugs, 18th Edition, 2015.CI: Penicillin G (P�zerpen®) W, NS, D5W: 7d1
NS, D5W: 24h at RT250,000 U/mL
PI: P�zer, Wyeth; Philadelphia PA, 2012.CI: Piperacillin/tazobactam(Zosyn®)
W, NS, D5W: 7dW, NS, D5W: 24h at RT0.1125 g/mL
30/15 mg/mL20/10 mg/mL PI: P�zer; New York NY, 2014.
Antibiotic (brand name) ReferenceConcentration Stability at 4˚C
Ampicillin 30 mg/mL≤20 mg/mL
Ampicillin/sulbactam(Unasyn®)
W: 48h; NS: 24hW: 72h; NS: 48h; D5W: 1h PI: P�zer; New York NY, 2010.
W, NS: 48hW, NS: 72h; D5W: 4h
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: Genentech USA; South San Francisco CA, 2015.Ceftriaxone (Rocephin®) NS: 23d; D5W: 26d1
W, NS D5W: 10d2
100 mg/mL PI: Bristol-Myers Squibb; Princeton NJ, 2013Aztreonam (Azactam®) W, NS: 7d
18 mg/mL ASHP's Handbook on Injectable Drugs, 18th Edition, 2015.Clindamycin (Cleocin®)a W, NS, D5W: 30d
100 mg/mL PI: Sano�-Aventis; Bridgewater NJ, 2007.Cefotaxime (Claforan®) W, NS, D5W: 5d
40 mg/mL100 to 200 mg/mL
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: GlaxoSmithKline; Research Triangle Park NC, 2004.3. Bornstein et al. Am J Hosp Pharm. 1974; 31:296-98.
Cefazolin (Ancef®) NS: 56d; D5W: 91d1
W, NS, D5W: 102-14d3
60 mg/mL100 mg/mL
1. Walker SE et al. Can J Hosp Pharm. 2010;63:212-24.2. PI: GlaxoSmithKline; Research Triangle Park NC, 2004.3. PI: Hospira Worldwide; Lake Forest IL, 2014.
Ceftazidime (Fortaz®, Tazicef®) NS: 10d1
W, NS, D5W: 7d2,3
20 mg/mLBing CM, Nowobilski-Vasilios A, American Society of Health-System P. Extended stability for parenteral drugs. Bethesda, Md.:American Society of Health-System Pharmacists; 2013.
Daptomycin (Cubicin®) NS: 10d
40 mg/mL100 mg/mL
page 11
page 12
Administering Intravenous(IV) Medications:Fluid viscosity is a critical factor when determining �ow rates with the FREEDOM60® Syringe Infusion System. Please call RMS Medical Products if you have any questions: 1-800-624-9600.
Guide to Selected RMS Precision Tubing Rates for FREEDOM60®
Note: This chart above is intended for medications with low viscosity.
DO NOT use this chart for viscous medications, such as IgG. Medications with greater viscosity will �ow signi�cantly slower and can be compensated for by using a faster �ow rate tubing set.
Time for 10 mL Time for 20 mL Time for 30 mL Time for 40 mL Time for 50 mL Time for 60 mL
F2 (2 mL/h) 5 h 10 h 15 h 20 h 25 h 30 h
F3 (3 mL/h) 3 h 20 min 6 h 40 min 10 h 13 h 20 min 16 h 40 min 20 h
F3.8 (3.8 mL/h) 2 h 38 min 5 h 16 min 7 h 54 min 10 h 32 min 13 h 10 min 15 h 48 min
F5 (5 mL/h) 2 h 4 h 6 h 8 h 10 h 12 h
F8 (8 mL/h) 1 h 15 min 2 h 30 min 3 h 45 min 5 h 6 h 15 min 3 h 30 min
F10 (10 mL/h) 60 min 2 h 3 h 4 h 5 h 6 h
F30 (30 mL/h) 20 min 40 min 60 min 1 h 20 min 1 h 40 min 2 h
F45 (45 mL/h) 13 min 27 min 40 min 53 min 67 mi 80 min
F60 (60 mL/h) 10 min 20 min 30 min 40 min 50 min 60 min
F120 (120 mL/h) 5 min 10 min 15 min 20 min 25 min 30 min
F180 (180 mL/h) 3.5 min 6.7 min 10.5 min 14 min 17.5 min 21 min
F275 (275 mL/h) 2.2 min 4.4 min 6.5 min 8.7 min 11 min 13 min
Tubing Set(rate mL/h)
Syringe Volume
Pharmacy Sample Calculations - FREEDOM60®
Product Dose Concentration Total Volume
Approximate Delivery Time
Delivery Rate
(mL/h)
Final Medication Delivery Rate
(mg/min)
RMS Precision Tubing Set
1 g 40 mg/mL 25 mL 33 min 45 30.30 mg/min F45
1 g 100 mg/mL 10 mL 40 min 15 25.00 mg/min F15
2 g 40 mg/mL 50 mL 67 min 45 29.85 mg/min F45
2 g 100 mg/mL 20 mL 80 min 15 25.00 mg/min F15
1 g 16.7 mg/mL 60 mL 60 min 60 16.67 mg/min F60
1 g 16.7 mg/mL 60 mL 80 min 45 12.50 mg/min F45
1 g 16.7 mg/mL 60 mL 120 min (2 h) 30 8.33 mg/min F30
1.5 g 25 mg/mL 60 mL 120 min (2 h) 30 12.50 mg/min F30
Rocephin® (ceftriaxone)
Vancomycin
Times are approximate and referenced for adult patients only. Pharmacy should verify that the �nal concentration and administration rates are within their protocols and adjust the RMS Precison tubing as necessary to obtain the desired infusion time.
page 13
More pro�tability with FREEDOM60®
The Real-World Experience of one Hospital-a�liatedHome Infusion Pharmacy
What % of your supply cost is allocated to the Freedom Infusion System or Elastomerics?
Cost per day when patient infuses 1x a day:
Cost per day when patient infuses 2x a day:
Cost per day when patient infuses 3x a day:
Pharmacy cost considerationsincluded in this analysis are:supplies, delivery, salaries, over-head warehouse, administrationbuilding taxes, fees, and �xed costs.
Note: This data was voluntarily providedby a domestic home care pharmacy thathas been using the FREEDOM60® for anti-biotics in high volumes for 10 years. Theyservice roughly 1,000 antibiotic patientsper year.
Per DiemDoses/Day Set/Syr Elast Set/Syr Elast Set/Syr Elast Set/Syr Elast Set/Syr Elast Set/Syr Elast
1 34% 29% 25% 22% 20% 18% 17% 15% 15% 13% 13% 11%2 37% 58% 44% 44% 22% 35% 18% 29% 16% 25% 14% 22%3 40% 88% 30% 66% 24% 53% 20% 44% 17% 38% 15% 33%4 43% 117% 32% 88% 26% 70% 21% 58% 18% 50% 16% 44%6 49% 175% 37% 131% 29% 105% 24% 88% 21% 75% 18% 66%
$15.00 $20.00 $25.00 $30.00 $35.00 $40.00
Percentage of DAILY COGs for Set/Syr ($4.63)* vs. Elasto ($4.38)**
* Price determined by averaging set $4.30/4.96 per day plus $0.45 per syringe per frequency** Price determined by averaging 100 ml Elasto at $3.75/5.00
page 15
Infusion Mats are a proven way to increase patient compliance andenhance the teaching/learning process.
The IV Infusion Mat from RMS helps your patients create a sanitary �eld and check their supplies before infusion. You can support consistent best practices with the mat’s easy to follow graphics.
Step-by-step guides to infusing antibiotics with Freedom Dynamic Equilibrium Pumps™ (FREEDOM60® and FreedomEdge™) areavailable upon request. Please call us at 800-624-9600 to haveyour guide(s) sent out today.
Introduction to the AntibioticInfusion Mat
page 14
Commercial Payer with Per Diems – Cost of Goods based on daily frequency for 4 weeks
More pro�tability with FREEDOM60®(continued)
States that are billing A&E Codes*:AL, AR, AZ, CA, CO, CT, DE, FL, GA, IA,ID, IL, IN, KS, KY, LA, MD, ME, MS, ND,NE, NH, NY, OH, OK, PA, RI, SD, TN,TX, UT, WA, WV, WY, NV, NM.
Based on per diem type coding and allowances and cost per goods,the use of the FREEDOM60® pump is far more economical to use for
antibiotics that require more than one infusion per day.- CLPI Consulting
Which codes to bill?*E0779 is a mechanical syringe pumpfor infusions 8 hours or more.E0780 is a mechanical syringe pump forinfusions less than 8 hours which is thedescription that matches the use of thisdevice for antibiotics.K0552 is for supplies used with a syringepump, each unit is based on the numberof containers. (NOT SETS)A4221 is for weekly catheter care supplies.It is billed one unit per week. This codemay be billed with K0552 when it is usedfor non sub-q infusions.
*From NHIA 2015 Poster: The Use of a PortableSyringe Infusion System for Antibiotic Infusions
by William E. Miller, Jr., RPh and Mala Crossley, BS, PharmD
Doses/Day Set/Syringe Elastomeric2 $154.84 $245.283 $167.44 $367.924 $180.04 $490.566 $205.24 $735.84
$0.00
$100.00
$200.00
$300.00
$400.00
$500.00
$600.00
$700.00
$800.00
Avg Cost of Goods Based on Daily Frequency for 4 Weeks
Set/Syringe Elastomeric
2 3 4 6Doses per Day
If you would like to calculate your savings, please contact your
RMS Strategic Account Manager.